About Regeneron
Regeneron news and updates
Regeneron launched 3 trail data for REGEN-COV on Nov 8th 21'.
This morning, Regeneron released their phase 3 trail data for REGEN-COV, showing 4 injections provide up to 81.6% protection against symptomatic COVID-19.
Jan 1, 2021 | contagionlive.comRegeneron partners with Agilent Technologies, Inc.
Regeneron and Sanofi developed Libtayo and partnered with Agilent for the use of PD-L1 IHC 22C3 pharmDx to evaluate PD-L1 expression in patients in the pivotal EMPOWER-Lung 1 clinical trial.
Jan 1, 2021 | selectscience.netRegeneron is developing monoclonal antibodies
Human fetal liver obtained from aborted babies was used in several key studies to humanize the mice Regeneron uses to produce monoclonal antibodies---a fact that is not disclosed on the publicly available literature on the REGN-COV2 antibody cocktail.
Jan 1, 2022 | fetalindustry.comRegeneron launched Employee Resource Groups on Jan 1st 21'.
In 2021, Regeneron launched six Employee Resource Groups, which provide professional development opportunities with leadership roles and support from members of senior leadership and executive sponsors.
Jan 1, 2022 | westchestermagazine.comRegeneron invests into assets : campus in the amount of $1.39B in Tarrytown, New York, United States
The Westchester County Industrial Development Agency has approved financial incentives for Regeneron Pharmaceutical’s $1.39 billion expansion of its Tarrytown campus.
Jan 1, 2022 | westchestermagazine.comRegeneron is developing portfolio of antibody treatment on Oct 2nd 17'.
In its own news release today, Regeneron also announced a new collaboration with BARDA to develop a portfolio of antibody treatment targeting 10 pathogens, starting with influenza.
Jan 1, 2017 | umn.eduRegeneron receives award two awards
He has a Ph.D. in chemistry and worked as a scientist for Regeneron Pharmaceuticals, where he won two awards for his contributions to developing groundbreaking antibody drugs.
Jan 1, 2021 | digitalbusinessmagazine.infoRegeneron is developing gene therapy product on Apr 6th 22'.
ViGeneron GmbH, a next-generation gene therapy company, today announced a target-specific strategic collaboration and option agreement with Regeneron Pharmaceuticals Inc. (Regeneron) to develop and commercialize a gene therapy product based on ViGeneron’s novel engineered recombinant adeno-associated virus vectors (vgAAVs) to treat an inherited retinal disease (IRD).
Jan 1, 2022 | biospace.comRegeneron is developing anti-IL-33 antibody, itepekimab
Sanofi and Regeneron, marketer of asthma heavy hitter Dupixent, is working on an anti-IL-33 antibody, itepekimab, for COPD.
Jan 1, 2022 | fiercebiotech.comViGeneron GmbH partnered with Regeneron on Apr 6th 22'.
German gene therapy company ViGeneron has entered a target-specific strategic collaboration and option agreement with US biotech Regeneron Pharmaceuticals (Nasdaq: REGN) to develop and commercialize a gene therapy product based on ViGeneron’s novel engineered recombinant adeno-associated virus vectors (vgAAVs) to treat an inherited retinal disease (IRD).
Jan 1, 2022 | thepharmaletter.comRegeneron launched Dupixent on Mar 1st 17'.
A more immediate threat: Sanofi and Regeneron introduced Dupixent, an IL-4 and IL-13 blocker, for the treatment of more severe eczema cases in March.
Jan 1, 2017 | fiercepharma.comOcular Therapeutix, Inc. partners with Regeneron
Ocular Therapeutix, Inc. has collaboration agreement with Regeneron Pharmaceuticals, Inc. for the development and commercialization of products using its hydrogel in combination with large molecule VEGF-targeting compounds for the treatment of retinal diseases.
Jan 1, 2018 | fairfieldcurrent.comRegeneron is developing vgAAV candidates
ViGeneron and Regeneron will work to develop vgAAV candidates against an undisclosed inherited retinal disease target.
Jan 1, 2022 | fiercebiotech.comDecibel Therapeutics, Inc. partners with Regeneron
Decibel is developing DB-OTO in collaboration with Regeneron Pharmaceuticals.
Jan 1, 2017 | catalent.comRegeneron acquired Checkmate Pharmaceuticals, Inc. for $250M on Apr 19th 22'.
Another notable news was Regeneron announcing that it was acquiring clinical-stage biotech Checkmate Pharmaceuticals in a $250M all-cash deal.
Jan 1, 2022 | seekingalpha.comRegeneron partners with SpringWorks Therapeutics
Regeneron additionally announced that it is collaborating with SpringWorks Therapeutics in a clinical trial to evaluate REGEN5458 in combination with nirogacestat, a therapeutic born by SpringWorks.
Jan 1, 2022 | biospace.comRegeneron launches Data Literacy program
At this session, Regeneron’s Vinay Dheer (Director, Data & Analytics Culture, Strategy and Literacy) will explore how Regeneron launched a Data Literacy program targeting its entire 10,000+ workforce.
Jan 1, 2022 | qlik.comRegeneron receives financing of $450M in from the federal government
Regeneron Pharmaceuticals has received $450 million through Operation Warp Speed to make and supply its COVID-19 vaccine candidate, REGN-COV2.
Jan 1, 2020 | abc6.comRegeneron receives financing of $70M in grant from the state
Despite its size, the $70 million grant to Regeneron is not expected to face much opposition from the board, whose members are appointed by the governor and Legislature.
Jan 1, 2019 | timesunion.comElicio partners with Regeneron
USA-based clinical-stage biotech Elicio Therapeutics has entered into a clinical supply agreement with Regeneron Pharmaceuticals (Nasdaq: REGN) to evaluate the safety and efficacy of Elicio’s lead asset, ELI-002, an investigational KRAS-targeted cancer vaccine, in combination with Regeneron’s Libtayo (cemiplimab), a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T cells, in patients with KRAS-driven tumors.
Jan 1, 2022 | thepharmaletter.comRegeneron partners with Ultragenyx Pharmaceutical Inc.
Regeneron is responsible for developing and distributing Evkeeza in the U.S. and is collaborating with Ultragenyx ( RARE ) to develop and sell Evkeeza outside the U.S.
Jan 1, 2022 | seekingalpha.comSanofi Genzyme sells assets to Regeneron in the amount of $1.1B
(Bloomberg) -- Regeneron Pharmaceuticals Inc. agreed to buy the immune-oncology drug Libtayo from partner Sanofi for as much as $1.1 billion, revisiting a deal that helped the French company re-enter the field of cancer research.
Jan 1, 2022 | yahoo.comRegeneron acquires Libtayo for $1.1B
(Bloomberg) -- Regeneron Pharmaceuticals Inc. agreed to buy the immune-oncology drug Libtayo from partner Sanofi for as much as $1.1 billion, revisiting a deal that helped the French company re-enter the field of cancer research.
Jan 1, 2022 | yahoo.comRegeneron is developing 18 different combinations using Libtayo
But Regeneron is testing 18 different combinations using Libtayo.
Jan 1, 2022 | investors.comRegeneron will invest into assets : global rights to cancer drug Libtayo in the amount of $900M on Jun 9th 22'.
June 2 (Reuters) - Regeneron Pharmaceuticals said on Thursday it would make an upfront payment of $900 million to buy the global rights to cancer drug Libtayo from Sanofi SA .
Jan 1, 2022 | yahoo.comRegeneron is developing cemdisiran for IgAN
Alnylam ( ALNY ) has partnered with Regeneron ( REGN ) to develop cemdisiran for IgAN, an inflammatory condition affecting the kidney, often leading to kidney failure.
Jan 1, 2022 | seekingalpha.comRegeneron increases headcount by 1000
Hochul announced Regeneron plans to create at least 1,000 new full-time, high-skill jobs in the Mid-Hudson Region over the next five years.
Jan 1, 2022 | hudsonvalleycountry.comUltima Genomics will partner with Regeneron on Jan 1st 23'.
Ultima Genomics, Inc. (the Company) has signed an agreement with Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN ) to further advance Ultima Genomics' sequencing architecture.
Jan 1, 2022 | ultimagenomics.comRegeneron partnered with Alnylam Pharmaceuticals, Inc. on Mar 21st 18'.
Based on these findings, Regeneron today also announced a collaboration with Alnylam Pharmaceuticals to discover RNAi therapeutics for this gene target.
Jan 1, 2018 | geisinger.orgRegeneron filed suit against Mylan on Aug 3rd 22'.
Regeneron filed a complaint yesterday against Mylan in the U.S. District Court for the Northern District of West Virginia, alleging infringement of twenty-four patents under the BPCIA based on Mylan’s submission of an aBLA for M710, a proposed biosimilar of EYLEA (aflibercept).
Jan 1, 2022 | jdsupra.comSignum Health Ltd partners with Regeneron
Signum Health Ltd has also been partnering with Regeneron to jointly develop the antibody combination Ronapreve™ (casirivimab and imdevimab, known as REGEN-COV™ in the US).
Aug 22, 2022 | prnewswire.co.ukRegeneron receives award The Arc New York’s Employer Recognition Award
One of The Arc Westchester’s longstanding employment partners, Regeneron Pharmaceuticals, has been honored with The Arc New York’s Employer Recognition Award.
Aug 24, 2022 | arcwestchester.orgOncoResponse, Inc. partnered with Regeneron on Sep 7th 22'.
OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of elite cancer responders, today announced a clinical supply agreement with Regeneron for PD-1 inhibitor Libtayo® (cemiplimab).
Sep 7, 2022 | biospace.comSanguinebio partners with Regeneron
Sanguine BioSciences, Inc., in collaboration with Regeneron Pharmaceuticals, is conducting this research study.
Aug 28, 2022 | apstype1.orgRegeneron hires Smita P Pillai as Chief DE&I Officer
Regeneron, a US-based biotechnology company that invents life-transforming medicines for people with serious diseases, has appointed Smita P Pillai, former Global Head of Diversity, Equity & Inclusion (DE&I) at Zendesk, as Chief DE&I Officer.
Sep 18, 2022 | hrnxt.comRegeneron promotes Melissa Lozner to compliance officer
And one more from biopharma: Regeneron has promoted Melissa Lozner, from deputy chief compliance officer to compliance officer.
Sep 22, 2022 | radicalcompliance.comRegeneron recognized as European Medicines Agency's (EMA) Committee for Medicinal Products on Oct 14th 22'.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Libtayo ® (cemiplimab) as a monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.
Oct 14, 2022 | prnewswire.comKoneksa Health, Inc. partners with Regeneron
In respiratory disease, Koneksa partnered with Regeneron to implement and validate mobile spirometry.
Oct 24, 2022 | tpmg.proRegeneron recognized as Best Biotechnology Product" of 2022 on Oct 28th 22'.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Inmazeb ® (atoltivimab, maftivimab, and odesivimab-ebgn) has been recognized as the "Best Biotechnology Product" of 2022 by the Galien Foundation, which acknowledges extraordinary scientific innovations that improve the human condition.
Oct 27, 2022 | regeneron.comRegeneron is developing higher-dose version of Eylea
Regeneron is working on a higher-dose version of Eylea that could be given every four months.
Jun 13, 2022 | fiercepharma.comRegeneron filed suit against Big Molecule Watch on May 1st 22'.
In May, Regeneron sued Amgen for antitrust in its marketing of cholesterol-lowering drug Repatha.
Aug 15, 2022 | fiercepharma.comCytomX Therapeutics, Inc. partnered with Regeneron on Nov 17th 22'.
Conditionally active antibody specialist Cytomx Therapeutics Inc. has agreed to work with Regeneron Pharmaceuticals Inc. to discover and develop new bispecific antibodies with what the partners said is the potential to "widen the therapeutic window and help minimize off-target effects."
Nov 17, 2022 | bioworld.comRegeneron is developing bispecific cancer therapies
The US biotech has nabbed a deal with Regeneron to develop bispecific cancer therapies by combining their respective technology platforms, getting $30m upfront in a positive twist of fate following a recent clinical trial challenge.
Nov 18, 2022 | informa.comGrey Wolf Therapeutics partnered with Regeneron on Nov 16th 22'.
Grey Wolf Therapeutics, a biotechnology company focused on generating entirely novel anti-tumour immune responses through targeted cancer neoantigen creation, today announced it has entered into a clinical supply agreement with Regeneron for their PD-1 inhibitor Libtayo ® (cemiplimab).
Nov 16, 2022 | prnewswire.comProtas partnered with Regeneron on Nov 16th 22'.
Protas, the non-profit organisation delivering smarter clinical trials for better health, today announced a strategic, long-term collaboration with Regeneron, a leading biotechnology company.
Nov 15, 2022 | protas.co.ukRegeneron receives financing of $5.6B
• New York-based Regeneron — which makes monoclonal antibody treatments for the virus — received $5.6 billion in DOD contracts.
Dec 7, 2022 | heraldandnews.comRegeneron recognized as DJSI World) for the fourth consecutive year and on the Dow Jones Sustainability North America Index (DJSI North America) for the third year at Dow Jones Sustainability World Index ( on Dec 12th 22'.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that the company has been included on the Dow Jones Sustainability World Index (DJSI World) for the fourth consecutive year and on the Dow Jones Sustainability North America Index (DJSI North America) for the third year.
Dec 12, 2022 | prnewswire.com